Minerva Neurosciences (NASDAQ:NERV) Rating Lowered to Sell at Wall Street Zen

Minerva Neurosciences (NASDAQ:NERV) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

A number of other equities analysts have also commented on NERV. HC Wainwright cut their price objective on shares of Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Minerva Neurosciences currently has a consensus rating of “Reduce” and an average price target of $4.00.

Minerva Neurosciences Stock Performance

Shares of NASDAQ:NERV opened at $4.32 on Friday. The company has a market capitalization of $186.93 million, a P/E ratio of -2.34 and a beta of -0.28. The company’s 50-day moving average is $3.99 and its 200 day moving average is $2.95. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). As a group, research analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Apella Capital LLC lifted its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,314 shares of the biopharmaceutical company’s stock after purchasing an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.